Replies to post #163671 on Biotech Values

[mcbio]

For all-oral HCV regimens, the cost of goods (excluding embedded royalties) will be trivial in the overall scheme of things.

Will be interesting to see how it plays out. Hopefully the HCV sector winds up being fruitful for the both of us. ; )